Freenome is a biotechnology company with a comprehensive multiomics platform for cancer detection using a routine blood draw.
Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages.The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention.Charles Roberts, Gabriel Otte, Riley Ennis, and Michael Otte launched the company in 2014 in South San Francisco, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 11, 2022 | Corporate Round | $290M | 1 | Roche | — | Detail |
Dec 7, 2021 | Series D | $300M | 31 | Perceptive Advisors RA Capital Management | — | Detail |
Aug 26, 2020 | Series C | $270M | 22 | Bain Capital Life Sciences Perceptive Advisors | — | Detail |
Jul 24, 2019 | Series B | $160M | 16 | Polaris Partners RA Capital Management | — | Detail |
Aug 28, 2017 | Series A | $7M | 12 | Section 32 | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Roche | Yes | Corporate Round |
Perceptive Advisors | Yes | Series D |
RA Capital Management | Yes | Series D |
Loxbridge Research | Yes | Seed |
Andreessen Horowitz | — | Series D |
ArrowMark Partners | — | Series D |
Artis Ventures (AV) | — | Series D |
Bain Capital Life Sciences | — | Series D |
BrightEdge Fund | — | Series D |
Byers Capital | — | Series D |